Concetta Di Mauro

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.

Journal: NPJ breast cancer
Published: June 07, 2022

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Journal: Oncotarget
Published: February 03, 2018

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.

Journal: British journal of cancer
Published: March 17, 2017

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Journal: Oncotarget
Published: March 21, 2016

Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen.

Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen.

Journal: International journal of molecular sciences
Published: February 05, 2016

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Journal: Oncotarget
Published: August 13, 2015

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Journal: Oncotarget
Published: March 04, 2015

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

Journal: British journal of cancer
Published: April 04, 2014

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.

Journal: British journal of cancer
Published: March 27, 2014
Showing 1-9 of 9

Last Updated: 09/26/2026